Audit: QRS - Lemongrass to Treat Cancer

Audit conducted on 29/08/2026 01:05 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	85
Failed	0
N/A	8
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Every gate item, tier item, protocol cell, marker row and qualitative item traces to a specific ER passage (ER lines 301–310, 283–299, 336–348, 391, 421–443, 465–469).
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“Unknowable” (time_3_value) and “The human reports are few, small, and mostly acute” (time_2_sub) carry the ER’s own hedges from ER lines 391 and 175.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindications remain contraindications and interactions remain interactions; no hedge is removed or added.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	No content from ER Benefit-Modifying Factors (lines 200–212) or Risk-Modifying Factors (lines 268–278) appears in any QRS card; each QRS section draws only from its mapped ER section.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, NCT identifiers, author names or brand names appear anywhere in the QRS.
1.6	The QRS does not introduce new attributions.	🟢	“practitioners of herbal and folk medicine” and “integrative clinics and supplement protocols” are the ER’s own attributions (ER lines 336, 338).

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	The sheet mirrors the ER’s sober “reproducible bench record, no human endpoint” framing.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Quantified targets and cadence give the reader actionable footing without overstating the evidence.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Content is presented as observed evidence and reference ranges, not orders.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperative clinical instructions appear in any populated variable.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	Gate lists name populations and agents; they do not instruct.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns occur in any populated variable.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms are confined to marker names and drug names, where they are unavoidable.
2.8	Information is presented in a concise and very compact manner	🟢	Gate and tier items are bare facts; protocol subs are one to two clauses.
2.9	It DOES NOT address the reader directly	🟢	Confirmed across the whole document; no “you”/”your”.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Functional reference ranges and a 12-marker panel address a proactive, testing-oriented reader.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Baseline, week-2, week-8–12 and 3–6 month monitoring assumes a reader willing to test repeatedly.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	No simplified general-population framing; the sheet assumes engagement with lab work and drug interaction detail.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	The at-a-glance leads with the bench-versus-human gap, which is the decision-relevant asymmetry for this audience.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	The term “anti-aging” does not occur in the QRS.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Register is clinical throughout; interaction row labels reproduce the ER’s own bold labels verbatim as required by item 4.2.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed strings match the template byte for byte (QRS lines 444, 481, 523, 543, 558, 579, 599, 603–605, 753); tier labels “Medium”, “Low”, “Speculative” are unmodified and the “High” spans are hidden, not renamed.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 34 singleton template variables plus the repeatable marker_#name/target/why and qualitative_item# rows are present; nothing is missing.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	A normalised structural diff against the template shows only the expected marker/qualitative row expansions and the two display:none additions; all other markup, comments and fixed text are untouched.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section mapped to a QRS variable is empty; the empty High tiers are governed by items 12.5 and 13.5, which mandate display:none instead of empty-state phrasing.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Protocol labels “Traditional infusion approach”, “Concentrated extract approach”, “Single versus split dosing” and all nine interaction labels reproduce the ER bold labels verbatim (ER lines 283–299, 336–348).
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Time-to-effect labels (“Calming effect”, “Blood pressure”, “Tumour effects”) are taken from the ER’s own wording at line 391; marker names are verbatim from the ER table (ER lines 423–434).
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	Zero emoji characters in the file; the ER’s 🟩/🟥/🟨/⚠️ markers were correctly dropped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed to the minimum the checklist permits — bare tier headings with no elaboration, gate items stripped to the key fact, and one-clause protocol subs; the marker and qualitative lists are at the completeness floor set by items 14.2 and 15.2.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14, immediately after the doctype at line 1.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening “—” at line 3, closing “—” at line 13.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; none of its values are echoed in the body.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:03" is quoted, correctly, because it contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: lemongrass_cancer_2026-0829-0002_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0829-0058.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the actual filename lemongrass_cancer_2026-0829-0002_Opus_QRS.html.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all ten keys; no stray whitespace or unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “Lemongrass to Treat Cancer - Quick Reference Sheet”; ER canonical_topic is “Lemongrass to Treat Cancer” and needs no entity encoding.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “Lemongrass to Treat Cancer”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: “08/29/2026”, the correct reformat of 2026-0829-0058.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header holds only the title and the template’s fixed subline; the ER’s “Also known as” line was not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Lines 433–437 compress ER Conclusion paragraphs 1, 3 and 4 into the bench-record / no-human-trial / mixed-safety decision frame.
7.2	[at_a_glance] is no longer than 60 words	🟢	58 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Bench record → ER line 465; no trial and none registered → ER line 465; tolerated tea amounts → ER lines 138/319/469; concentrated-form signals → ER line 469.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; the ER’s “DNA damage” is rendered as “genetic damage” and “altered handling of cancer drugs” as “drug-handling signals”.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial names, years, sample sizes or p-values.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numeric effect measures of any kind.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	Sourced from the “Populations who should avoid Lemongrass” list at ER lines 301–310.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All eight ER populations are present, none added (QRS lines 546–553).
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Eight discrete <li> elements inside the stop_items span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Rationale parentheses (“citral’s oestrogen-like prostate signal”, “untested oestrogen-receptor binding”, the Child-Pugh gloss, the aspiration note) are all stripped; no dashes or trailing clauses remain.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“Child-Pugh Class B or C”, “under 12”, “within 48 hours”, “symptomatic”, “curative-intent” and “hormone-receptor-positive” are all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s contraindication list uses no ranking notation inside parentheses.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names eight such populations and the section is correspondingly populated, not empty.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	Sourced from the nine interaction bullets at ER lines 283–299.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All nine interactions carried over; none duplicates a contraindication (QRS lines 561–569).
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Nine discrete <li> elements inside the caution_items span.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Every “Caution —”/”Monitor —” clause, consequence sentence and action sentence is stripped; the appositive “, a drug-expelling pump” is also removed.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	All six ER example-drug and example-supplement lists are preserved intact, as is “with narrow safety margins”.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s interaction parentheses contain plain comma-separated drug lists, no ranking notation.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names nine interactions and the section is correspondingly populated, not empty.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	Drawn from the ER Therapeutic Protocol bullets at lines 336, 338 and 348.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Infusion dose, concentrated-extract dose and dose splitting are the only three ER protocol bullets a reader can actually act on; “Research formulation approach” is explicitly unavailable in humans (ER line 340).
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies at least three distinct actionable aspects, so no set is unused.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine cells populated (QRS lines 448–477); values carry the ER’s own doses of 1–3 g / 1–3 cups, 100–500 mg daily, and two-or-three divided doses.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Calming, blood pressure and tumour effects are exactly the three aspects named in the ER Practical Considerations “Time to effect” bullet (line 391).
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Ordered Medium (situational anxiety) → Low (blood pressure) → Speculative/none (tumour), matching the ER benefit tiers at lines 157, 171 and 179.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three distinct time-to-effect aspects, so no set is unused.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine cells populated (QRS lines 487–515), each traceable to ER lines 159, 173–175 and 391.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER does provide time-to-effect information, so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	Every item corresponds to an ER Expected Benefits subheading (lines 151–197).
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present at QRS lines 525–536.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Items are the bare ER subheadings; the ER’s Magnitude: figures (6.9 points, p = 0.006, 1.78 to 1.22, etc.) are all omitted.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any benefits item; the ER’s “⚠️ Conflicted” marker on the DNA-damage item is also dropped.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	ER line 153 states no benefit reaches High; QRS line 525 sets benefits_high to style="display: none" with empty content.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	Every item corresponds to an ER Potential Risks & Side Effects subheading (lines 219–265).
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present at QRS lines 581–593.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Items are the bare ER subheadings; hazard ratios, confidence intervals and survival percentages from ER line 229 are omitted.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any risks item; the “⚠️ Conflicted” marker on DNA strand breaks is dropped.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	ER line 221 states no risk reaches High; QRS line 581 sets risks_high to style="display: none" with empty content.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Sourced from the ER Monitoring Protocol & Defining Success biomarker table (lines 421–434).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All twelve ER rows present in ER order: ALT, AST, total bilirubin, direct bilirubin, serum amylase, complete blood count, eGFR, fasting glucose, blood pressure, PSA, estradiol, tumour response marker or imaging. Ranges and “Why” text are verbatim.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	QRS lines 745–747 reproduce the ER’s baseline / week 2 / week 8–12 / every 3–6 months schedule including the chemotherapy-precedence caveat (ER line 419).

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	Sourced from the “Qualitative markers worth tracking alongside the panel” list at ER lines 438–443.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All six ER qualitative markers present and verbatim at QRS lines 756–771.

Issues 29/08/2026 01:05

Pass rate 100.00%. No issues found.